JP2022550345A5 - - Google Patents

Info

Publication number
JP2022550345A5
JP2022550345A5 JP2022519226A JP2022519226A JP2022550345A5 JP 2022550345 A5 JP2022550345 A5 JP 2022550345A5 JP 2022519226 A JP2022519226 A JP 2022519226A JP 2022519226 A JP2022519226 A JP 2022519226A JP 2022550345 A5 JP2022550345 A5 JP 2022550345A5
Authority
JP
Japan
Prior art keywords
optionally
amino acid
signaling molecule
cancer
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022519226A
Other languages
English (en)
Japanese (ja)
Other versions
JP7793511B2 (ja
JP2022550345A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/052764 external-priority patent/WO2021062184A1/en
Publication of JP2022550345A publication Critical patent/JP2022550345A/ja
Publication of JP2022550345A5 publication Critical patent/JP2022550345A5/ja
Priority to JP2025259819A priority Critical patent/JP2026048868A/ja
Application granted granted Critical
Publication of JP7793511B2 publication Critical patent/JP7793511B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022519226A 2019-09-26 2020-09-25 Pd-l1標的化キメラタンパク質及びその使用 Active JP7793511B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025259819A JP2026048868A (ja) 2019-09-26 2025-12-17 Pd-l1標的化キメラタンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906447P 2019-09-26 2019-09-26
US62/906,447 2019-09-26
PCT/US2020/052764 WO2021062184A1 (en) 2019-09-26 2020-09-25 Pd-l1 targeted chimeric proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025259819A Division JP2026048868A (ja) 2019-09-26 2025-12-17 Pd-l1標的化キメラタンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2022550345A JP2022550345A (ja) 2022-12-01
JP2022550345A5 true JP2022550345A5 (cg-RX-API-DMAC7.html) 2023-10-31
JP7793511B2 JP7793511B2 (ja) 2026-01-05

Family

ID=75166458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519226A Active JP7793511B2 (ja) 2019-09-26 2020-09-25 Pd-l1標的化キメラタンパク質及びその使用
JP2025259819A Pending JP2026048868A (ja) 2019-09-26 2025-12-17 Pd-l1標的化キメラタンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025259819A Pending JP2026048868A (ja) 2019-09-26 2025-12-17 Pd-l1標的化キメラタンパク質及びその使用

Country Status (7)

Country Link
US (1) US20230002493A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034565A4 (cg-RX-API-DMAC7.html)
JP (2) JP7793511B2 (cg-RX-API-DMAC7.html)
CN (1) CN114761430A (cg-RX-API-DMAC7.html)
AU (1) AU2020353660A1 (cg-RX-API-DMAC7.html)
CA (1) CA3151928A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021062184A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3890773A4 (en) * 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
JP2024527571A (ja) * 2021-07-08 2024-07-25 オリオンズ バイオサイエンス インコーポレイテッド インターロイキン-1アルファキメラタンパク質
US12559576B2 (en) 2021-11-11 2026-02-24 Regeneron Pharmaceuticals, Inc. CD20-PD1 binding molecules and methods of use thereof
JP2026525313A (ja) * 2023-07-14 2026-07-29 オハイオ ステート イノベーション ファウンデーション 抗体-薬物コンジュゲート、並びにそのリンカー及び使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101704734B1 (ko) * 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CA2712432C (en) * 2008-01-29 2018-09-25 Ablynx N.V. Methods to stabilize single variable domains
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US20140079691A1 (en) * 2012-09-20 2014-03-20 Anaptysbio, Inc. Thermostable antibody framework regions
CN106999583A (zh) * 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
US11661455B2 (en) * 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
AU2017384528A1 (en) * 2016-12-19 2019-07-04 Ichnos Sciences SA Novel TNFR agonists and uses thereof
FI3596116T3 (fi) * 2017-03-16 2023-11-09 Alpine Immune Sciences Inc Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
US11780930B2 (en) * 2017-06-08 2023-10-10 Black Belt Therapeutics Limited CD38 modulating antibody
GB201710973D0 (en) * 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
EP3664829A4 (en) * 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
US12564632B2 (en) * 2017-11-08 2026-03-03 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
JP7689079B2 (ja) * 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ,インコーポレイテッド 治療用インターフェロンアルファ1タンパク質

Similar Documents

Publication Publication Date Title
US11136413B2 (en) PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
JP2018523493A5 (cg-RX-API-DMAC7.html)
JP2021531754A5 (cg-RX-API-DMAC7.html)
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2022534837A5 (cg-RX-API-DMAC7.html)
RU2018139339A (ru) Новые биспецифические полипептиды против cd137
JP2021531764A5 (cg-RX-API-DMAC7.html)
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP2017149720A5 (cg-RX-API-DMAC7.html)
JP2021521275A5 (cg-RX-API-DMAC7.html)
HRP20230787T1 (hr) Anti-muc1 antitijelo
JP2019529373A5 (ja) 抗Tim−3抗体
HK1217958A1 (zh) 四价双特异性抗体
JP2019509055A5 (cg-RX-API-DMAC7.html)
EP3087097B1 (en) Multifunctional antibodies binding to egfr and met
JP2013505732A5 (cg-RX-API-DMAC7.html)
JP2024522949A5 (cg-RX-API-DMAC7.html)
JP2018522888A5 (cg-RX-API-DMAC7.html)
CN115894701A (zh) 结合cd3的抗体及其用途
JP2022532812A5 (cg-RX-API-DMAC7.html)
JP2021522347A5 (cg-RX-API-DMAC7.html)
JP2022512891A5 (cg-RX-API-DMAC7.html)
JP2020502233A5 (cg-RX-API-DMAC7.html)
CN121758617A (zh) 结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途
WO2024114676A1 (zh) Cldn18.2/4-1bb结合蛋白及其医药用途